Core Points - Amarin Corporation plc will host a conference call on July 30, 2025, at 8:00 a.m. ET to discuss its second quarter 2025 results and recent strategic steps [1][2] - The financial results will be released in the pre-market hours on the same day [2] Conference Call and Webcast Information - Access to the live call can be found on the investor relations section of Amarin's website, with specific dial-in numbers provided for both the United States and international participants [3] - A replay of the call will be available shortly after the live event through the company's website [3] Company Overview - Amarin is an innovative pharmaceutical company focused on cardiovascular disease management, with offices in multiple countries including the United States, Ireland, and Switzerland [4] - The company aims to enhance the scientific understanding of cardiovascular risk that persists beyond traditional therapies [4] Investor Communication - Amarin utilizes its website and investor relations section to communicate with investors and the public, providing access to various materials including presentations, SEC filings, and press releases [5] - The company encourages regular review of the information posted on these channels, which may include updates on social media [5]

Market Overview - The three major U.S. stock indexes closed lower last week, with the Dow Jones Industrial Average down 1%, the S&P 500 down 0.3%, and the Nasdaq Composite down 0.1% [1] - The market pullback was influenced by renewed U.S. tariff threats, particularly higher levies on Canada and the European Union, raising concerns about economic growth and inflation [2] Earnings Performance - Despite tariff concerns, many investors focused on strong earnings reports from airlines and consumer stocks, indicating a resilient economy [2] - The second-quarter earnings season is critical for assessing the impact of tariffs on corporate profits [3] Zacks Research Performance - Mogo Inc. shares surged 81.8% since being upgraded to Zacks Rank 2 (Buy) on May 8, significantly outperforming the S&P 500's 11.1% increase [4] - ATI Inc. also saw a 32.6% return since its upgrade to Zacks Rank 2 on May 6, compared to the S&P 500's 10.7% increase [5] - A hypothetical portfolio of Zacks Rank 1 (Strong Buy) stocks returned +6.51% in May 2025, outperforming the S&P 500's +4.47% [5] Zacks Recommendations - Amarin Corporation and European Wax Center shares increased by 62.6% and 49.9%, respectively, after being upgraded to Outperform on May 12, against the S&P 500's 10.5% rise [8] - The Zacks Focus List portfolio returned 8.84% in 2025 (through June 30) compared to the S&P 500's +6.21% [12] Portfolio Performance - The Zacks Earnings Certain Admiral Portfolio (ECAP) returned +3.20% in Q1 2025, outperforming the S&P 500's -4.30% decline [16] - The Zacks Earnings Certain Dividend Portfolio (ECDP) returned +5.74% in Q1 2025, compared to the S&P 500's -2.41% [20] - The Zacks Top 10 Stocks portfolio delivered +11.8% year-to-date through June 2025, outperforming the S&P 500's +6.2% [22] Long-term Performance - Since 2004, the Zacks Focus List portfolio has produced an annualized return of +11.60%, compared to +10.22% for the S&P 500 [15] - The Top 10 portfolio has generated a cumulative return of +2,246.8% since 2012, significantly outperforming the S&P 500's +502.3% [24]

Strategic Partnerships & Financial Restructuring - Amarin has entered into an exclusive license and supply agreement with Recordati to commercialize VAZKEPA in 59 countries, primarily in Europe[13] - The Recordati agreement includes $25 million in upfront cash[9] and up to $150 million in milestone payments based on net sales levels[9] - Global restructuring is expected to generate approximately $70 million in cost savings over the next 12 months[6, 16, 24] VAZKEPA/VAZKEPA Market & Growth - VAZKEPA has CVRR indication regulatory approvals in 49 global markets[7] - Demand for VASCEPA/VAZKEPA has grown by 77% in aggregate, comparing Q1 2025 to Q1 2024[22] - The company maintains over 40% share of the IPE market in the U S [21] US Market & Global Expansion - The refined commercial strategy in the U S focuses on payer coverage post-loss of exclusivity[21] - Partnerships in Rest of World are focused on maximizing patient access to VASCEPA globally, with commercialization across 11 countries and regulatory submissions pending in 8 additional markets[23]

Core Insights - Amarin's shares surged 27.3% following the announcement of an exclusive long-term licensing agreement with Recordati to commercialize its drug Vazkepa across 59 EU countries [1][6]. Licensing Agreement Details - The agreement grants Recordati exclusive rights to market Vazkepa in Europe, with Amarin receiving an upfront payment of $25 million and potential milestone payments of up to $150 million based on sales targets [4][6]. - Amarin expects to achieve approximately $70 million in cost savings over the next 12 months as part of a strategy to enhance growth and reduce operational costs [3][7]. Product and Market Context - Vazkepa is approved in the EU for treating severe hypertriglyceridemia and reducing cardiovascular event risks, similar to its approval in the U.S. under the name Vascepa [2]. - The drug is protected by patents until 2039 in the EU, which supports its market expansion efforts [3]. Financial Position and Growth Strategy - The licensing deal strengthens Amarin's cash position, with nearly $300 million in cash and no debt as of March-end [7]. - The partnership with Recordati is expected to enhance Amarin's financial strength and accelerate its path to positive cash flow through new revenue opportunities [7][8]. Industry Position - Amarin's stock has increased by 65.3% year-to-date, contrasting with a 4.2% decline in the industry [5]. - Recordati's established cardiovascular portfolio, which includes treatments for hypertension and heart failure, positions it well to expand the reach of Vazkepa [8].

Company Overview - Amarin (AMRN) shares increased by 27.3% to close at $16.04, with notable trading volume compared to typical sessions, and a 13.4% gain over the past four weeks [1][2] Recent Developments - Amarin licensed EU rights to its drug Vazkepa to Recordati, an Italy-based company, for $25 million upfront, with potential milestones of up to $150 million and ongoing royalties, significantly expanding Vazkepa's market reach and reducing EU-related costs by an expected $70 million over the next 12 months [2] Financial Performance - The company is expected to report a quarterly loss of $0.60 per share, a year-over-year change of -400%, with revenues projected at $45.19 million, down 33% from the previous year [3] - The consensus EPS estimate for the quarter has been revised 22.4% higher over the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Amarin is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like MannKind (MNKD), which saw a 5.1% increase in its last trading session [5] - MannKind's consensus EPS estimate has remained unchanged at $0.04, reflecting a -20% change from the previous year, and it currently holds a Zacks Rank of 3 (Hold) [6]

Amarin Corporation (AMRN) Conference Call Summary Company Overview - **Company**: Amarin Corporation - **Date**: June 24, 2025 - **Key Product**: VASCEPA (Veskepta in Europe) Core Industry Insights - **Industry**: Cardiovascular Pharmaceuticals - **Market Need**: Significant unmet need in cardiovascular disease treatment, particularly in Europe [5][9][31] Key Announcements - **Partnership with Recordati**: - Amarin has entered a long-term partnership with Recordati to commercialize VASCEPA in Europe [5][6] - Recordati is recognized for its extensive cardiovascular expertise and established infrastructure [5][6] - The partnership aims to enhance patient access to VASCEPA across Europe [5][9] Financial Highlights - **Upfront Payment**: Amarin will receive an upfront payment of $25 million [7] - **Milestone Payments**: Potential milestone payments up to $150 million based on Recordati's sales performance [7][25] - **Supply-Based Revenues**: Amarin will receive royalties and revenues from product supply, which are significant for the company [7][8] - **Cost Structure Improvement**: Expected cost savings of approximately $70 million over the next twelve months due to restructuring [13][14] Market Performance - **U.S. Sales**: Nearly 28 million prescriptions of VASCEPA have been written, with 2.4 million patients treated since launch [10] - **Global Strategy**: Focus on driving access and utilization in various international markets while maintaining a profitable U.S. business [10][15] Strategic Focus - **Restructuring**: Amarin plans to become a leaner organization to support global business and maximize shareholder value [8][19] - **Long-Term Vision**: The partnership with Recordati is seen as a critical step in executing Amarin's global strategy and strengthening its financial position [19][20] Competitive Landscape - **Complementary Positioning**: VASCEPA is positioned as a complementary therapy to existing LDL-lowering treatments, not a direct competitor [36][37] - **Market Dynamics**: The cardiovascular market is becoming increasingly crowded, but VASCEPA's unique clinical profile offers significant growth potential [36][38] Risk Factors - **Forward-Looking Statements**: The company cautions that actual results may differ from projections due to various risk factors, including market dynamics and operational challenges [2][3] Conclusion - **Future Outlook**: Amarin is optimistic about the partnership with Recordati and the potential for VASCEPA to address cardiovascular disease needs in Europe, while also maintaining a strong position in the U.S. market [19][20]

Core Points - Amarin Corporation has entered into a long-term licensing and supply agreement with Recordati S.p.A. to commercialize VAZKEPA in 59 countries, primarily in Europe, aiming to enhance the product's market reach and financial position [1][2] - The partnership is expected to generate approximately $70 million in cost savings over the next 12 months through streamlined global operations, particularly by reducing commercialization expenses in Europe [1][12] - Amarin's financial strength includes nearly $300 million in cash and no debt, positioning the company for accelerated positive cash flow [2][3] Company Strategy - The collaboration with Recordati is seen as a strategic move to leverage their expertise in the cardiovascular space, which aligns with Amarin's goal of maximizing long-term shareholder value [2][4] - Amarin will continue to focus on its U.S. operations, which are profitable and provide meaningful cash flows, while also exploring international partnerships to enhance revenue generation [12] Financial Terms of the Agreement - Amarin will receive an upfront payment of $25 million and potential milestone payments up to $150 million based on Recordati's commercial sales performance [5] - The agreement includes supply-based revenues and royalties from the commercialization of VAZKEPA [5] Market Context - Recordati is a well-established pharmaceutical company with a strong presence in the cardiovascular market, which constitutes about 25% of its Specialty and Primary Care business [3] - The partnership is expected to enhance the commercial opportunity for VAZKEPA in Europe, where Amarin holds patent protection until 2039 [2][4]

Core Viewpoint - Amarin Corporation PLC (AMRN) is showing potential for a bullish breakout as it has reached a key support level and formed a "golden cross" in its moving averages [1][2]. Technical Indicators - A "golden cross" occurs when a short-term moving average (50-day) crosses above a long-term moving average (200-day), indicating a potential bullish trend [2]. - The formation of a golden cross typically follows a downtrend, a crossover of moving averages, and culminates in an upward price movement [3]. Performance Metrics - AMRN has experienced a rally of 25.2% over the past four weeks, suggesting strong momentum [4]. - The company currently holds a 2 (Buy) rating on the Zacks Rank, indicating positive market sentiment [4]. Earnings Outlook - There have been no cuts to earnings estimates for the current quarter, with three revisions higher in the past 60 days, contributing to a positive earnings outlook [4]. - The Zacks Consensus Estimate for AMRN has also increased, further solidifying the bullish case for the stock [4]. Investment Consideration - Given the technical indicators and positive earnings revisions, investors are encouraged to consider adding AMRN to their watchlist [6].

Company Performance - Amarin (AMRN) has returned 36.6% year-to-date, significantly outperforming the average loss of 2.3% in the Medical sector [4] - The Zacks Consensus Estimate for AMRN's full-year earnings has increased by 57% over the past three months, indicating improved analyst sentiment and a positive earnings outlook [3] Industry Context - Amarin is part of the Medical - Biomedical and Genetics industry, which consists of 502 individual stocks and currently ranks 78 in the Zacks Industry Rank [5] - The average performance of the Medical - Biomedical and Genetics industry has seen a loss of 0.6% year-to-date, further highlighting Amarin's strong performance relative to its peers [5] Sector Ranking - The Medical group, which includes Amarin, is currently ranked 6 within the Zacks Sector Rank, which evaluates 16 different sector groups [2] - Amarin holds a Zacks Rank of 2 (Buy), suggesting a favorable investment outlook [3][4]

Core Viewpoint - Amarin (AMRN) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Amarin's Earnings Outlook - For the fiscal year ending December 2025, Amarin is expected to earn -$2.50 per share, unchanged from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Amarin has increased by 57%, reflecting a positive trend in earnings estimates [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [9][10].